Daniel T. Ruan

Daniel T. Ruan

Auto-generated profile, based on publicly available information

Daniel T. Ruan

Cancer Research Institute, Beth Israel Deaconess Cancer Center, Department of Medicine and Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2014 in Surgery
Verified
Journal Article
Closed access
JIJames C. Iannuzzi
James C. Iannuzzi
FFFergal Fleming
Fergal Fleming
KKKristin N. Kelly
Kristin N. Kelly
DRDaniel T. Ruan
Daniel T. Ruan
JMJohn R. Monson
John R. Monson
JMJacob Moalem
Jacob Moalem

30 April 2017 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
WGWilliam J. Gibson
William J. Gibson
DRDaniel T. Ruan
Daniel T. Ruan
VPVera Paulson
Vera Paulson
JBJustine A. Barletta
Justine A. Barletta
GHGlenn J. Hanna
Glenn J. Hanna
EAEliezer Van Allen
Eliezer Van Allen
Purpose: Cancers may resist single-agent targeted therapies when the flux of cellular growth signals is shifted from one pathway to another. Blockade of multiple pathways may be necessary for effective inhibition of tumor growth. We document a case in which a patient with anaplastic thyroid carcinoma (ATC) failed to respond to either mTOR/PI3K or combined RAF/MEK inhibition but experienced a dramatic response when both drug regimens were combined. Experimental Design: Multi-region whole-exome sequencing of five diagnostic and four autopsy tumor biopsies was performed. Meta-analysis of DNA and RNA sequencing studies of ATC was performed. Results: Sequencing revealed truncal BRAF and PIK3CA mutations, which are known to activate the MAPK and PI3K/AKT pathways, respectively. Meta-analysis demonstrated 10.3% cooccurrence of MAPK and PI3K pathway alterations in ATC. These tumors display a separate transcriptional profile from other ATCs, consistent with a novel subgroup of ATC. Conclusions: BRAF and PIK3CA mutations define a distinct subset of ATC. Blockade of the MAPK and PI3K pathways appears necessary for tumor response in this subset of ATC. This identification of synergistic activity between targeted agents may inform clinical trial design in ATC. Clin Cancer Res; 23(9); 2367–73. ©2016 AACR.

1 December 2015 in Journal of Cancer Policy
Verified
Journal Article
Closed access
SMShilpa S. Murthy
Shilpa S. Murthy
NENir Eyal
Nir Eyal
ONOle Frithjof Norheim
Ole Frithjof Norheim
DRDaniel T. Ruan
Daniel T. Ruan
GNGeorges Ntakiyiruta
Georges Ntakiyiruta
RRRiviello Robert
Riviello Robert


3 April 2023
Verified
Other
Open access
CCChen Li Chew
Chen Li Chew
ALAndrea Lunardi
Andrea Lunardi
Federico GulluniFederico Gulluni
Federico Gulluni
DRDaniel T. Ruan
Daniel T. Ruan
MCMing Chen
Ming Chen
PPPier Paolo Pandolfi
Pier Paolo Pandolfi
Supplementary Figure 2. Validation of INPP4B antibody.